The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream

TitleThe molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream
Publication TypeMiscellaneous
Year of Publication2014
AuthorsSmall, EJay, Youngren, J, Beer, TM, Ryan, CJ, Thomas, G, Pourmand, N, Reiter, REvan, Alumkal, JJ, Stuart, JM, Evans, CP, ,